Analysed RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ) News Sources
Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting
14-09-2026
yahoo.com
Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
17-08-2026
yahoo.com
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
20-08-2026
yahoo.com
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
26-08-2026
yahoo.com
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
09-09-2026
yahoo.com
What is the current price of RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ)?
The current price of RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ) is $1.08.
RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ) absolute price change since previous trading day?
The absolute price change of RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ) since the previous trading day is $-0.0364.
RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ) percentage price change since previous trading day?
The percentage price change of RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ) since the previous trading day is -3.2605%.
What is the most recent average sentiment score for RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ)?
The most recent average sentiment score for RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ)?
The most recent sentiment for RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ) is .
SEC-8K** Filing Available For RADIOPHARM THERANOSTICS LTD (RADX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.